Cardiket Retard

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Cardiket Retard

Property Description
Active ingredient Isosorbide Dinitrate (ISDN)
Form Extended-release tablet (Retard)
Pharmacological class Nitrate Vasodilator
General purpose Supportive management of heart function
Origin Synthetic compound (Organic Nitrate)

What Type of Medicine is Cardiket Retard?

Cardiket Retard is a pharmaceutical preparation classified as an Antianginal medicine and specifically as a Nitrate Vasodilator. Its primary component is the active ingredient, Isosorbide Dinitrate (ISDN). Isosorbide Dinitrate is clinically recognized for its function as a vasodilator, which is its ability to widen blood vessels, promoting systemic support for the heart.

The medication belongs to the organic nitrate pharmacological class and is dispensed as a prescription-only single-ingredient product. Its therapeutic role is centered on continuous, supportive management, particularly in scenarios requiring reliable long-term maintenance of the circulatory system.


Composition and Form: Understanding Isosorbide Dinitrate Retard

The medication’s sole active component, Isosorbide Dinitrate, is a synthetic compound derived from the glucitol chemical structure. The preparation is manufactured as an extended-release tablet, a characteristic designated by the term "Retard". This specific oral dosage form functions as a delayed-action preparation, engineered to release the active component gradually over many hours. This sustained-release profile is specifically designed to minimize fluctuations in blood concentrations, providing continuous therapeutic support, distinguishing it from immediate-release forms.


What is the General Purpose of Cardiket Retard?

The general purpose of the medication is to support heart function by ensuring a more favorable balance between the heart's energy needs and the delivery of oxygen. This action is achieved because Isosorbide Dinitrate acts as a Nitric Oxide donor, which subsequently causes the relaxation of the smooth muscle walls of the vasculature. The resulting widespread vasodilation contributes to a crucial reduced cardiac workload by lessening the pressure against which the heart pumps. This foundational, long-acting effect is essential for the drug’s utility as a supportive agent in maintaining cardiovascular efficiency during ongoing management.

Advertisements

What side effects are possible with Cardiket Retard?

Cardiket Retard: Official Safety Information

This section describes the officially documented adverse effects and general safety characteristics of Isosorbide Dinitrate extended-release, as listed in regulatory documents (such as the FDA label and EMA Summary of Product Characteristics). The profile is characterized by effects resulting from the medication's intended action as a vasodilator.

Adverse Reactions by Frequency

The most frequently observed adverse reaction, classified as Very Common in official documents, is headache. This effect, often termed 'nitrate headache,' and dizziness are most frequently reported at the initiation of treatment or during dose increases, and generally tend to diminish with continued use. Reactions classified as Common typically include hypotension (low blood pressure), reflex tachycardia (increased heart rate), nausea, and vomiting.

Frequency Classification Officially Listed Adverse Reaction Examples
Uncommon Flushing, Allergic skin reactions, Circulatory collapse, Syncope
Very Rare Exfoliative dermatitis

Serious Safety Constraints

The regulatory labeling defines strict safety constraints where the medication must not be used. There is an absolute contraindication for use with Phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil) due to the risk of life-threatening severe hypotension and circulatory collapse. The medication is also contraindicated in patients with conditions such as severe hypotension, cardiogenic shock, marked anemia, and specific heart diseases like hypertrophic obstructive cardiomyopathy.

Specific safety considerations in official documents include a general caution for dose selection in geriatric patients and the notation that use during pregnancy and lactation is generally not recommended unless considered essential.

Advertisements

Overdose and Emergency Response

An overdose of Cardiket Retard (Isosorbide Dinitrate) is documented in official regulatory sources as an acute medical emergency. The overdose presentation is defined by severe physiological instability stemming from excessive vasodilation, primarily affecting the cardiovascular system. Manifestations include a rapid fall in blood pressure (hypotension), tachycardia, severe, persistent throbbing headache, vertigo, and visual disturbances. Gastrointestinal symptoms such as nausea, vomiting, or bloody diarrhea may also occur.

Life-threatening outcomes explicitly documented in regulatory labeling include circulatory collapse, seizures (convulsions), and a rare, severe blood complication known as methemoglobinemia. The official guidance mandates that individuals seek emergency medical help immediately or contact a Poison Control center if an overdose is suspected, as manifestations can rapidly escalate.

Management focuses on symptomatic and supportive treatment, including careful volume expansion to manage hypotension. Regulatory documentation notes that no specific antagonist is known for the primary vasodilator effect, and certain arterial vasoconstrictors are advised against during intervention. Populations such as infants and those with underlying cardiovascular disease are noted to have increased susceptibility to severe effects, requiring careful monitoring.

Advertisements

Therapeutic Uses of Cardiket Retard

What Cardiket Retard Treats: Main Uses and Benefits

The purpose of Cardiket Retard, an extended-release nitrate, is to provide continuous, supportive management across specific chronic cardiovascular conditions. It is commonly used in contexts where long-term symptomatic assistance is needed. This medication is generally considered relevant for easing symptoms related to systemic imbalance and overall physiological strain.


Therapeutic Focus and Symptom Management

The medication is applied to address two primary therapeutic domains: the prophylactic management of chronic stable angina pectoris and supportive symptom relief in chronic heart failure.

For chronic stable angina, the long-acting nature of the therapy helps address symptom clusters that may become intense or disruptive during flare-ups. This continuous support helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations.

When used with other medications, it is also relevant for easing symptoms related to heart failure, specifically those linked to organ-specific functional stress, such as shortness of breath and physical limitations. The sustained support may help patients cope more steadily with symptom fluctuations, assisting with easing the impact of symptomatic manifestations on routine activities.


Quick Fact: Relief for Recurrent Chest Discomfort

Quick Fact: Relief for Recurrent Chest Discomfort The primary therapeutic purpose is the prevention of recurrent anginal episodes.

Regulatory References

  1. MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cardiket Retard — Official Regulatory Information

The eligibility profile for Cardiket Retard (Isosorbide Dinitrate extended-release) is strictly defined by regulatory health authorities, outlining specific absolute prohibitions and use limitations.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) are the primary population with established use.
Populations for whom use is contraindicated Patients with a known allergy or hypersensitivity to isosorbide dinitrate or other nitrates. Patients who are taking Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil, vardenafil). Patients taking the soluble guanylate cyclase (sGC) stimulator riociguat.
Age-related eligibility rules Pediatric Use: Safety and effectiveness have not been established in children and adolescents. Geriatric Use: Use with caution; dose selection should be cautious due to a greater frequency of decreased organ function.
Condition-specific eligibility rules Prohibited in: Severe hypotension (e.g., systolic BP below 90 mmHg) or acute circulatory failure (shock). Caution required in: Severe liver or renal disease, and certain heart conditions like hypertrophic obstructive cardiomyopathy.
Pregnancy and lactation eligibility status Pregnancy (US Category C): Use only if the potential benefit justifies the potential risk to the fetus. Lactation: It is unknown whether the drug is excreted in human milk; caution should be exercised.

Eligibility Classifications (High-Level)

Category Regulatory Statement
Eligibility severity classification Absolute Contraindication (Co-administered PDE-5 Inhibitors/sGC Stimulators, Hypersensitivity). Use Not Established (Pediatric Patients). Conditional Use/Caution (Geriatric, Severe Hypotension, Organ Impairment).

Resulting Eligibility Structure

Official regulatory documents define eligibility through absolute contraindications that prohibit use with specific classes of co-administered medications due to profound hypotensive risk. Use is further restricted by age, as the drug's effect is not established in children, and by clinical state, requiring caution or avoidance in patients with pre-existing severe hypotension or compromised organ function.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Cardiket Retard (Isosorbide Dinitrate) is defined primarily by its vasodilatory action, resulting in mandated restrictions and cautions against co-administration with other specific medicinal products and substances.


Documented Contraindications and Restrictions

Co-administration with Phosphodiesterase-5 (PDE5) inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) is strictly contraindicated due to the officially documented risk of severe, life-threatening hypotension and cardiovascular collapse. This severe interaction risk also applies to the soluble guanylate cyclase (sGC) stimulator Riociguat, which is also contraindicated for use with Cardiket Retard.


Pharmacodynamic Potentiation

Many other medicinal products have an officially documented additive or potentiating effect on hypotension when co-administered. This includes all other blood pressure lowering drugs, such as beta-blockers, calcium antagonists, ACE-inhibitors, and other vasodilators. Additionally, co-administration with certain neuroleptics and tricyclic antidepressants may also potentiate the hypotensive effect.


Substance and Exposure Interactions

Alcohol (Ethanol) is officially documented to have an additive effect in lowering blood pressure. Furthermore, regulatory documents specify that the nitrate may increase the blood level and the resulting hypertensive effect of co-administered Dihydroergotamine. Caution is also officially recommended with substances like Saproterin that affect nitric oxide metabolism.

Advertisements

Mechanism of Action

Cardiket Retard (Isosorbide Dinitrate) functions as a prodrug that requires enzymatic bioactivation, primarily by mitochondrial ALDH2, to release the signaling molecule, Nitric Oxide (NO). NO then activates the enzyme soluble Guanylate Cyclase (sGC) inside the vascular smooth muscle cells. This action initiates the cGMP cascade, resulting in the dephosphorylation of the myosin light chain and subsequent relaxation of the smooth muscle fibers, leading to widespread vasodilation.

This vasodilation is significantly stronger in the veins (capacitance vessels) than in the arteries. This differential effect causes peripheral blood pooling, reducing the volume and pressure of blood returning to the heart, a parameter known as cardiac preload. This systemic adjustment decreases the mechanical load and wall tension exerted on the myocardium, which is the primary physiological consequence of the mechanism.

The mechanism is subject to Nitrate Tolerance, a constraint where continuous exposure impairs bioactivating enzymes and desensitizes sGC. To restore the mechanism's responsiveness, the system necessitates a recovery period known as a nitrate-free interval.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Cardiket Retard

Cardiket Retard, an extended-release preparation of isosorbide dinitrate, is designed exclusively for oral administration. The general usage principles are strictly governed by the need to maintain consistent therapeutic concentration while preventing the development of drug tolerance, a phenomenon known as tachyphylaxis.


Standard Adult Regimens and Dosages

The medication is intended for long-term management and is generally utilized in a daily regimen that ensures a period of low drug concentration to maintain efficacy. Treatment typically begins with an extended-release dose of 40 mg taken once daily. The usual maintenance range for this formulation is 40 mg to 160 mg per day, which may be adjusted based on official prescribing information, with a maximum daily dosage generally considered to be 160 mg.


Administration Instructions and Timing

The physical form of the medication dictates specific administration instructions necessary for proper release kinetics. The extended-release tablet must be swallowed whole with fluid and must not be crushed, chewed, or divided under any circumstances, as this would compromise the sustained-release mechanism. The tablet may be taken with or without food.

The frequency is typically once or twice daily. The administration schedule must incorporate a prolonged nitrate-free interval of at least 14 hours in a 24-hour period. This is a critical component of the official use pattern and must be observed to minimize tolerance. If the dose is divided, the two administrations are typically spaced asymmetrically (e.g., 6 to 8 hours apart) to preserve this essential drug-free period.


Use Duration and Special Populations

Use is intended as a long-term course. Discontinuation of therapy must not be abrupt; the dose should be gradually reduced under medical supervision to avoid a sudden worsening of symptoms. For older adults, official labeling generally advises initiating therapy using the lowest recommended dose.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cardiket Retard


Evidence for Prophylactic Management of Recurrent Chest Discomfort

Research examined the medicine in the context of chronic stable angina pectoris, a condition characterized by fluctuating or episodic manifestations of chest discomfort. The research design included short-term Randomized Controlled Trials (RCTs) and systematic reviews that explored short-term symptom changes. Studies primarily monitored outcomes related to physical discomfort, specifically the number of anginal episodes and the usage of rescue nitrates. These trials was evaluated in adult populations presenting with this specific condition where symptoms may vary in intensity.

Research describes patterns monitored during the short-term evaluation periods, where outcomes related to episodic chest discomfort were measured. Research highlights observed patterns related to the monitored use of fast-acting rescue medication. Further studies reported observations related to measured outcomes in physical activity duration before certain symptoms appeared during controlled testing.

Evidence for Supportive Management in Chronic Heart Failure

The medicine was evaluated in the context of chronic heart failure, a condition marked by functional limitations. Initial research involved short-term hemodynamic studies that monitored acute changes in the circulatory system, specifically measuring pressure within the heart chambers. Larger, long-term clinical trials were conducted, primarily exploring short-term symptom changes when the medicine was observed in combination with another vasodilator.

These combination studies research examined major clinical endpoints, including rates of hospital admission related to heart failure and outcomes related to long-term patient status. Studies report on the outcomes related to systemic or functional imbalance measured in the observed populations, and findings in these combination trials describe patterns related to observed rates of hospitalization and mortality.

Duration of Follow-Up and Long-Term Data

The duration of studies supporting the use of the medicine varies widely. Many functional trials focused on research exploring short-term symptom changes, meaning they were observed in timeframes of just weeks or a few months. In contrast, the major clinical outcome trials, especially those using the medicine in combination, utilized longer follow-up periods.

Despite these longer observational periods, the full understanding of observed symptom patterns and their duration over many years in all patient groups, particularly with monotherapy, is an area where long-term effects are not fully established.

Key Studies & References Isosorbide: Indications, Mechanism of Action, and Adverse Effects (StatPearls/NCBI Bookshelf) - Evidence for Nitrate Tolerance

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cardiket Retard (FAQ)


Q: Is Cardiket Retard used for sudden chest pain or only to prevent attacks?

Official information for extended-release isosorbide dinitrate indicates it is used primarily to prevent attacks of chest pain (angina). Because of its slow-release nature, it is not suitable or effective for treating an episode of angina once it has begun, as it does not act quickly enough for acute symptoms.


Q: How is Cardiket Retard different from other medicines used for angina, like immediate-release tablets?

Immediate-release forms of the active ingredient typically require more frequent dosing. In contrast, the extended-release formulation is designed for once-daily or twice-daily use to provide a sustained, long-acting anti-anginal effect over a period of many hours, according to official product information.


Q: How soon after starting Cardiket Retard might a person notice a change in their symptoms?

Clinical data suggests the onset of action for the extended-release formulation is delayed compared to immediate-release versions. The intended anti-anginal effect is generally noted to be present about one hour after a dose. The full pattern of symptom changes or relief may take time to establish.


Q: Are there any long-term health concerns associated with using Cardiket Retard for many years?

The main long-term constraint cited in regulatory documents is the development of tolerance, which requires a proper dosing schedule to prevent. Official observations in industrial workers exposed to high doses over long periods suggested physical dependence and rebound effects upon sudden withdrawal. Regulatory warnings indicate the dose must be gradually reduced under medical guidance.


Q: Are there specific food or drink items, like alcohol or grapefruit, that should be avoided while taking this medicine?

Regulatory documents state that alcohol can have an additive effect in lowering blood pressure, which may increase side effects like dizziness. While grapefruit is not consistently cited in official documents as a major restriction, non-government sources recommend consulting a healthcare professional about other supplements or foods.


Q: Can Cardiket Retard cause dizziness or lightheadedness when standing up?

Yes, regulatory documents explicitly warn that severe hypotension, particularly with an upright posture (known as orthostatic hypotension), may occur. This blood pressure drop can result in dizziness, lightheadedness, or fainting, especially when standing up quickly from a seated or lying position.


Q: Can this medication affect a person's ability to drive or operate machinery?

Official safety information includes a caution that the medication may affect coordination and reaction time. Patients are advised to avoid driving or operating machinery if symptoms like dizziness or lightheadedness occur.


Q: What is the process for gradually stopping Cardiket Retard if a person needs to?

Official usage instructions state that treatment should not be stopped abruptly to avoid a sudden worsening of symptoms. Instead, the dose should be gradually reduced under medical supervision. The specific dose reduction schedule is individualized and determined by the healthcare provider.


Q: Does Cardiket Retard affect a person's kidney function?

Regulatory caution exists for patients who have severe renal (kidney) disease. This indicates that the medication's use requires careful consideration in this specific population.


Q: Does Cardiket Retard affect a person's liver function?

Regulatory guidelines advise caution when the medicine is used by patients with severe liver disease. Since the medicine is primarily processed by the liver, existing impairment is a factor in its use.


Q: Can this medicine cause swelling in the ankles or feet?

Swelling in the ankles or feet, known medically as peripheral edema, is listed in some regulatory safety data. This is described as a common side effect observed in studies when the medicine was used in certain heart conditions, such as left ventricular failure.


Q: Can Cardiket Retard cause a fast or pounding heartbeat?

Yes, official safety documents list an increased heart rate, medically termed reflex tachycardia, as a common side effect. This effect is described as a physiological response where the body attempts to counteract the medication's blood pressure lowering effect.


Q: Is Cardiket Retard known to be habit-forming or addictive?

Regulatory documents mention the potential for physical dependence, which is distinct from psychological addiction. Observations in industrial workers with high-dose, long-term exposure to nitrates showed that sudden withdrawal could lead to rebound effects. For this reason, official use guidelines state that the dose should be gradually reduced under medical guidance.


Q: Are there any reported interactions between Cardiket Retard and herbal supplements?

Official patient guidance notes that there is generally not enough safety information to confirm that herbal remedies and supplements are safe to take with this active ingredient. Patients are advised to consult their healthcare provider for guidance.


Q: What is the risk of an overdose with Cardiket Retard?

Regulatory documents indicate that the effects of an overdose are related to severe lowering of blood pressure and widespread widening of blood vessels (vasodilatation). Symptoms may include severe dizziness, a faint pulse, profuse sweating, headache, nausea, and potentially a condition called methemoglobinemia, where breathing may become difficult.


Q: What should a person do if they forget to take a dose of Cardiket Retard?

Regulatory patient instructions generally describe skipping the missed dose and taking the next dose at the regular scheduled time. Patients are generally advised against taking extra medicine to compensate for a missed dose.


Q: Does Cardiket Retard help with exercise tolerance for people with angina?

Yes, clinical trials of the active ingredient have demonstrated effective reductions in exercise-related angina. Studies report that patients' ability to perform physical activity before experiencing symptoms was significantly greater than that observed in patients taking a placebo.


Q: What should a person know about taking Cardiket Retard before having surgery or dental work?

Official patient information states the importance of informing the doctor, surgeon, or dentist about the use of the active ingredient before any type of surgery, including dental procedures.

Advertisements

How should Cardiket Retard be stored and disposed of?

Storage and Disposal Requirements

Official labeling defines strict conditions for storing and disposing of Cardiket Retard (Isosorbide Dinitrate extended-release tablets).


Storage Conditions

  • Temperature: Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
  • Protection: The tablets must be protected from light and moisture and should be kept from freezing.
  • Container: Store in a well-closed, light-resistant container. Do not use the medicine if its original packaging or blister is damaged.

Disposal and Safety

  • Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.
  • Disposal: Unused or expired medicine must be disposed of in accordance with local regulations or as instructed by a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardiket Retard found in:

A-Z Index: